TREATMENT OF THE PERIPHERAL T LYMPHOMAS (PTCL)

ALINA CĂTANĂ1, CLAUDIA PODIA IGNA2, M. DEAC3

1 Clinical Emergency County Hospital of Sibiu, 2 Astra Polyclinic of Sibiu, 3 University of Sibiu

INTRODUCTION

PTCL treatment includes prophylactic treatment for NHL HTLV positive and a curative one. It is based on 1) general measures, 2) chemotherapy (standard doses or high doses, maintenance chemotherapy, chemotherapy in relapse/resistance to therapy), 3) radiotherapy 4) biological modulators, 5) antiretroviral therapy, 6) monoclonal antibodies therapy, 7) prospects for gene therapy, 8) surgical measures.

Prophylactic treatment for HTLV infection. No treatment currently exists to eradicate the HTLV virus; that is why prophylaxis, prevention, patient education are necessary. The virus is transmitted through blood, semen, vaginal fluids, breast milk. Among those infected with HTLV 1-90% are carriers and only 1-4% can make the adult T-cell lymphoma or tropical spastic paraparesis. Breast feeding is not recommended because most T lymphomas are in advanced stages of the disease, stage III and IV. It can be used as monotherapy just in cutaneous and nasal forms. Patients with mediastinal disease, stage III and IV. It can be used as monotherapy just in cutaneous and nasal forms. Patients with mediastinal localization have also a therapeutic benefit.

Immunotherapy is recently investigated and used in addition to conventional chemotherapy. The answer to this is to be evaluated. Immunotherapy in lymphoma is a new and exciting area of research in the last 10 years. It uses modified T cells multiplied, re-infused, directed against tumor cells. Existe altor comorbidități cu linfoamele T conferă un prognostic extrem de prost necesitând adaptarea și îmbunătățirea regimurilor terapeutice.

ANTI CD30 antibodies(9), anti CCR 4 antibodies.
The effect of antitumor vaccines directed against the idiotypic TCR in cutaneous T lymphomas. Involvement of tumor suppressor genes in the pathogenesis of PT represents a potential candidate for molecular target therapy; gene therapy uses adenoviral vectors to mediate gene p53 transfer (15,3,4,5,6).

2. Chemotherapy: Standard therapeutic regimens

**CHOP type** (cyclophosphamide 750mg/m², vincristin 1.4mg/m², Plerixafor 50mg/m² day 1, Prednisone 40mg/m² days 1-5) is maintained as basic therapy in T lymphomas but with disappointing results with the exception of ALCL. Large trials compare CHOP with chemotherapeutic regimens of IInd and IIIrd generation. Following regimens can be used DHAP, ASHAH, PitMICEBO, mBACOD, ACVB, NCVB, VCAP-AMP-VECP, VIM, ACVM, CTVP, protocolone LNH 87, hyperCHOP, MBACOS, MINE, hyperCVAD, CHOP + Etoposid + Gemzar (16,16). The results suggest that the high toxicity regimens must be balanced with higher rate of complete responses. Agents as paclitaxel, topotecan, flavopiridol may be modulators of kinase-dependent cyclin with activity in hematologic malignancies, particularly NK lymphomas.

Nucleoside analogues have proven effective in these subtypes of lymphomas in the few studies performed. Fludarabine, pentostatine, oxicoguanozine analogue, was demonstrated activity in relapsed lymphoma, in relapsed PTCL. Fludarabine, pentostatine, oxicoguanozine and especially in those with ATLL detected with HTLV. The response was improved after relapse in PTCL as single agent or in combination with other agents, gave favorable results in several studies performed in PTCL and MF (18). Compound 506a78, oxiconoguanozine analogue, was used in PTCL, but grade 3-4 neurotoxicity and drug-related early mortality limit its use. (19)

Danileukin difitox (ONTAK), approved by the U.S. since 2000, is a fusion protein between interleukin-2 molecules and peptide sequences of the active enzyme and translocated domain of diphtheria toxin membrane and is targeted interleukin 2 receptor on T cells. It is used effectively for cutaneous T lymphoid cells, phosphorylated derivatives of analogues induce apoptosis and decrease ribonucleotide reductase and inhibition of replication and DNA repair. They are used in mycosis fungoides and PTCL with cutaneous determination. Gemcitabine plus cisplatin in patients with relapsed PTCL as single agent or in combination with other agents, gave favorable responses in several studies performed in PTCL and MF (18). Compound 506a78, oxiconoguanozine analogue, was used in PTCL, but grade 3-4 neurotoxicity and drug-related early mortality limit its use. (19)

Danileukin difitox (ONTAK), approved by the U.S.

Baxoter, Bexarotene (Targetetin, LGD 1069) is an oral agent, a synthetic selective retinoic agonist approved in 2007 by the U.S. FDA for patients with refractory / relapsed mycosis fungoides and in other cutaneous T lymphomas. Side effects are: hypertriglyceridemia, fatigue, pruritus, leukopenia, rash. There is also a form of topical gel application

**Inhibitors of deacetylated histones** Acetylated histones modulates gene expression, cell differentiation, survival and are regulated by histonacetitransferase and histonodeacetilase (HDAC). HDAC inhibition gives rise to acetylated nucleosomal histones which induce apoptosis in transformed cells, decreasing cell proliferation. (14)

**Depsipeptides, Duclizumab** (registered in October 2007)

**Vorinostat** (21,22)- have demonstrated activity in relapsed PTCL with an overall response rate of 26%. Nellarabin (deoxiguanosin derivative) was recently approved for children with T cell leukemia, lymphoblastic lymphoma (42), in ATL and aggressive NK cell lymphomas and in LGL (large granular cell).

**Bone marrow transplant (BMT)** The role of autologous and allogenic bone marrow transplant in T lymphomas is not well defined. BMT role in first relapse is accepted that the standard. High doses of chemotherapy are followed by bone marrow transplant. It is used to extend survival in PTCL. Several small trials await the demonstration of the role of high doses chemotherapy followed by stem cells transplant. The studies are quite difficult to interpret due to heterogeneity of lymphomas’ subtypes. The answer is different depending on the type of transplant (allo or auto transplant), the time of administration (primitive or lymphoma in relapse or refractory to salvage therapy), and depending on whether or not the pediatric cases are included.(23,24) In the absence of randomized trials, using high dose chemotherapy and stem cell transplant as first line treatment has shown superiority over conventional therapy. Patients with relapse, who showed initial chemosensitivity, respond favorably to high-dose chemotherapy and stem cell transplant with long-term survival rate of 35-54%. The outcome of patients with refractory PTCL is less favorable with low long-term survival rate, although other reports reveal a 5 year survival rate of 37%. Resistance mechanisms are due to the rise of multidrug-resistance and to suppression of gene P53. (15)

The success rate varies with the pre-transplant IPI (international prognostic index) and histological subtype so ALCL demonstrate their superiority in response rate and survival compared with PTCLUS. However favorable results for patients with ALK + ALCL does not extend to cases ALK-. BMT in T / NK lymphomas can be used as part of salvage therapy in chemosensitive patients in relapse. In ATL, allogenic BMT was perfected in a few patients with inconsistent results due to problems of survival.

**Allogenic stem cells transplant in PTCL** was performed on some small series of highly selected patients.

**Mortality with treatment is greater in patients receiving allogenic transplant after fully myeloablative regimen.** (25) Reduction of conditioning intensity is an attractive strategy for patients at increased risk of treatment toxicity, but this can not be used in patients with aggressive lymphoma because it would decrease the response rate. The response was improved after leukocytes infusion from the donor by increasing graft effect versus lymphoma.

**Antiviral therapy:** interferon-α and zidovudine combination results in an average survival of 11-18 months with an initial response rate of 70-90% in patients with T lymphoma and especially in those with ATLL detected with HTLV positive. Another combination was interferon α and Combivir (Zidovudine + Lamivudine). In general, it is choose concomitant chemotherapy and antiviral therapy using antiviral monotherapy in maintenance treatment for an indefinite period in general or determined by viremia evolution under treatment.

There are several treatment procedures established for MF / SS: topical therapy using skin applications of cytostatic agents or UVB or dinitrofluorobenzene; Photochemotherapy uses UV A or B radiation to accumulate in the skin where it is decomposed by ultraviolet light (PUVA). (26)

For localized lymphomas, intestinal lymphomas, surgery remains the basic treatment; appropriate reduction of tumor mass has repercussions on response to treatment and therefore on survival.

In general in T lymphoma it can not be used monotherapy being either surgery, radiation or antiviral therapy; instead a comprehensive treatment must be adopted including in combination results in an average survival of 11-18 months with an initial response rate of 70-90% in patients with T lymphoma and especially in those with ATLL detected with HTLV positive. Another combination was interferon α and Combivir (Zidovudine + Lamivudine). In general, it is choose concomitant chemotherapy and antiviral therapy using antiviral monotherapy in maintenance treatment for an indefinite period in general or determined by viremia evolution under treatment.

There are several treatment procedures established for MF / SS: topical therapy using skin applications of cytostatic agents or UVB or dinitrofluorobenzene; Photochemotherapy uses UV A or B radiation to accumulate in the skin where it is decomposed by ultraviolet light (PUVA). (26)

For localized lymphomas, intestinal lymphomas, surgery remains the basic treatment; appropriate reduction of tumor mass has repercussions on response to treatment and therefore on survival.

In general in T lymphoma it can not be used monotherapy being either surgery, radiation or antiviral therapy; instead a comprehensive treatment must be adopted including in combination results in an average survival of 11-18 months with an initial response rate of 70-90% in patients with T lymphoma and especially in those with ATLL detected with HTLV positive. Another combination was interferon α and Combivir (Zidovudine + Lamivudine). In general, it is choose concomitant chemotherapy and antiviral therapy using antiviral monotherapy in maintenance treatment for an indefinite period in general or determined by viremia evolution under treatment.

There are several treatment procedures established for MF / SS: topical therapy using skin applications of cytostatic agents or UVB or dinitrofluorobenzene; Photochemotherapy uses UV A or B radiation to accumulate in the skin where it is decomposed by ultraviolet light (PUVA). (26)

For localized lymphomas, intestinal lymphomas, surgery remains the basic treatment; appropriate reduction of tumor mass has repercussions on response to treatment and therefore on survival.
general chemotherapy, adjusting treatment according to patient’s performance status, taking into account the results of international studies, experience, patient compliance, drug availability in the country, the possibility of enrollment in clinical studies.

BIBLIOGRAPHY

2. Hyun Ju Lee, MD, Jung-Gi Im, MD, Jin Mo Goo, MD, Kyong Won Kim, MD, Byung Ihn Choi, MD, Kee Hyun Chang, MD, Joon Koo Han, MD and Moon Hee Han, MD. Department of Radiology and the Institute of Radiation Medicine, Seoul National University College of Medicine, Peripheral T-Cell Lymphoma: Spectrum of Imaging Findings with Clinical and Pathologic Features : Radiographics, vol23, nr1, 2003, pg 7-26
7. Erin Gaza, Craig Y Okado : Tumor cell Lymphocite- Pulsed dendritic cells are more effective than TCR Id Protein vaccine. MD Anderson Cancer Center: Immunotherapy of T Cell Lymphoma . J immunol 2009; 169:5227-5235
12. Moura IC et al. A neutralizing monoclonal antibody (mAb A24) directed against the transferrin receptor induces apoptosis of tumor T lymphocytes from ATL patients, Blood 2004; 103:1838-1845
24. Andrei Shustov,Kerry Savage. Does high dose therapy and autologous hematopoietic stem Cell Transplantation have a role in the primary treatment of peripheral cell Lymphomas?. Hematology,2008,39-41